^
Association details:
Biomarker:KRAS G12C
Cancer:Lung Cancer
Drug Class:KRAS G12C inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

2789 / 12 - Tumor suppressor genotype dramatically impacts lung cancer response to KRAS G12C inhibitors in vivo

Published date:
03/15/2023
Excerpt:
To uncover genotypes that are particularly important in controlling the response of tumors to oncogenic KRAS inhibition, we applied this platform to quantify the impact of 59 tumor suppressor genes on KRASG12C-driven lung tumor responses to G12Ci. Treatment resulted in approximately three-quarters reduction in both average tumor sizes and overall tumor burden...